Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc.
Your view on ESLA
Overview
What the company does, where it operates, and who runs it.
About Estrella Immunopharma, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Cheng Liu
- Headquarters
- 5858 Horton Street, EmeryVille, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Cheng Liu
- Headquarters
- 5858 Horton Street, EmeryVille, CA, US
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Infographics
Visual summary of the business at a glance.
Media
Videos and interviews covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Comparables
List of peer companies in the same industry.
Institutional Ownership
Which funds and firms own the stock.
Insider Trading
Recent buying and selling by company executives.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
News
Latest headlines and market coverage.